What is chronic urticaria?

Chronic urticaria is the occurrence of wheals (hives), angioedema or both for more than 6 weeks. Wheals are itchy, raised, red or white skin lesions that appear and disappear within 24 hours (individual lesions), leaving no marks. Angioedema is deeper swelling of the skin, lips, throat, tongue, hands or genitalia. Chronic spontaneous urticaria (CSU) is the most common form — no identifiable physical trigger (distinguished from inducible urticarias that are triggered by cold, pressure, exercise, etc.). CSU affects approximately 1% of the population globally, causing profound impact on sleep, daily activities and quality of life. Most episodes of CSU resolve spontaneously within 1-5 years, though recurrence is common.

What causes chronic urticaria?

In most patients with CSU, the exact cause is not identified (hence "idiopathic"). In approximately 40-50%, an autoimmune mechanism is implicated — IgG autoantibodies targeting either the high-affinity IgE receptor (FCεRI) on mast cells or IgE itself → direct mast cell activation → histamine release without an external allergen trigger. A small proportion of CSU is caused by identifiable triggers: chronic infections (H. pylori, dental infections — debated); thyroid autoimmune disease; thyroid hormone abnormalities; NSAID/aspirin intolerance (in approximately 30% — exacerbates CSU through COX-1 inhibition); food additives (less common than believed). Comprehensive allergy testing (food allergy panels) is not routinely recommended in CSU — it rarely identifies a cause and often leads to unnecessary dietary restriction.

What are the treatment options?

EAACI/WAO 2022 stepladder: Step 1: Second-generation H1 antihistamine at licensed dose (cetirizine 10mg, loratadine 10mg, fexofenadine 180mg, bilastine 20mg) — first-line for 2-4 weeks. Step 2: If inadequate response — up-dose antihistamine to 2-4× the licensed dose (e.g. cetirizine 20-40mg daily) — try for 4 weeks. Step 3: If still inadequate — add omalizumab (Xolair) 300mg SC every 4 weeks — second-line; specialist prescription; approximately 40-65% achieve complete symptom control. Step 4: If omalizumab fails or is unavailable — cyclosporin 3-5mg/kg/day (monitor renal function); or other immunosuppressants (mycophenolate, hydroxychloroquine — off-label). Note: corticosteroids are only for short-term crisis management, not maintenance.

Can food allergy cause chronic urticaria?

Commonly believed, but rarely true: genuine IgE-mediated food allergy causes acute urticaria (within minutes to 2 hours of food ingestion) — not chronic daily urticaria. Chronic spontaneous urticaria (occurring daily or near-daily without relationship to specific food ingestion) is essentially never caused by IgE-mediated food allergy. Extensive food allergy testing (skin prick tests, IgE RAST panels to dozens of foods) is not recommended by EAACI/WAO guidelines for CSU — it has very low diagnostic yield and frequently leads to unnecessary dietary restriction without benefit. However: NSAID/aspirin sensitivity (COX-1 inhibition releasing arachidonic acid → prostaglandin shift → mast cell activation) affects approximately 30% of CSU patients and should be enquired about — aspirin and NSAIDs should be avoided if they worsen symptoms.

How long does chronic urticaria last?

CSU is self-limiting in most patients — but the timeline is variable: Approximately 50% of CSU patients are clear within 1 year of onset. An additional 20-30% clear within 3-5 years. Approximately 10-20% have persistent disease beyond 5 years. Predictors of longer duration: positive autoimmune markers (anti-FCεRI or anti-IgE autoantibodies); angioedema; comorbid autoimmune thyroid disease; family history. The good news: most patients with CSU eventually achieve spontaneous remission — even severe, omalizumab-dependent disease can remit after years of treatment. Omalizumab can be slowly tapered (spacing injections from 4-weekly to 6-weekly to 8-weekly) once symptoms are controlled — some patients achieve drug-free remission.

How does GMJ News cover chronic urticaria?

GMJ News covers EAACI/WAO 2022 step treatment, antihistamine up-dosing, omalizumab 2014 approval and mechanism, UAS7 scoring, autoimmune mechanism (anti-FCεRI), thyroid autoimmunity screening, CSU vs inducible urticaria, QoL data (=coronary artery disease), food allergy misconception, cyclosporin for refractory cases, and natural history of CSU. Chronic urticaria is directly relevant to PHIG's allergy and dermatology programme and clinical practice in Georgia.

Home › Topics › Chronic Urticaria

Chronic Urticaria

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Chronic urticaria (CU) — recurrent wheals (hives) and/or angioedema lasting more than 6 weeks — is a highly burdensome skin condition affecting approximately 1% of the global population at any time, most commonly as chronic spontaneous urticaria (CSU) in which no specific external trigger can be identified (distinguishing it from allergic urticaria), with a profound impact on sleep, daily activities and quality of life comparable in burden to triple coronary artery disease (WHO/WAO). The treatment revolution was omalizumab (Xolair, anti-IgE) — FDA/EMA-approved in 2014 for CSU refractory to antihistamines — which achieves complete symptom control in approximately 40-65% of antihistamine-resistant patients, transforming a previously untreatable-feeling condition into one with a highly effective biological therapy, while the majority of patients with milder CSU respond excellently to second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine) at standard or up to 4× licensed doses (EAACI/GA²LEN guidelines).

Key messages

1% of population — QoL comparable to coronary artery disease

Chronic urticaria affects approximately 1% of the global population at any time. A landmark EuroQoL study found that chronic spontaneous urticaria impairs quality of life comparably to triple-vessel coronary artery disease — a striking finding that underscores the profound impact of an apparently "minor" skin condition.

Omalizumab — the transformative second-line treatment (FDA/EMA 2014)

Omalizumab (Xolair, anti-IgE monoclonal antibody) was FDA/EMA-approved in 2014 for chronic idiopathic urticaria (CSU) refractory to antihistamines — achieving complete symptom control in approximately 40-65% of patients and dramatically reducing burden. SC injection 300mg every 4 weeks. Transformed a previously treatment-resistant condition.

Second-generation antihistamines first-line — up to 4× the licensed dose

EAACI/GA²LEN/WAO guidelines: second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine, bilastine) are the cornerstone first-line treatment. If standard dose (1× licensed dose) is insufficient after 2-4 weeks: up-dose to 2-4× the licensed dose. Evidence supports up-dosing in CSU with improved efficacy and acceptable safety. First-generation antihistamines (chlorphenamine, diphenhydramine) are NOT recommended for CSU due to sedation and short duration of action.

Autoimmune mechanism — mast cell activation

Chronic spontaneous urticaria (CSU) is driven by mast cell and basophil activation, causing histamine and cytokine release → transient wheals (pruritic, blanching, <24h per individual lesion) and angioedema. Approximately 40-50% of CSU is autoimmune — driven by IgE autoantibodies against FCεRI (the high-affinity IgE receptor) or against IgE itself. Omalizumab's mechanism: binds free IgE → reduces FCεRI expression on mast cells/basophils → reduces mast cell activation.

CSU vs inducible urticaria — important distinction

Chronic spontaneous urticaria (CSU): wheals with no identifiable physical trigger. Inducible urticaria: wheals triggered by specific physical stimuli — dermographism (stroking/pressure); cold urticaria; cholinergic urticaria (exercise/sweat/heat); solar urticaria; aquagenic urticaria; pressure urticaria (delayed). Treatment differs: antihistamines ± avoidance of triggers for inducible; omalizumab effective for some inducible types (cold, dermographism).

Thyroid autoimmunity — check in chronic urticaria

A significant proportion of CSU patients have autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease) — associated with the autoimmune mechanism of CSU. Check: TSH, anti-TPO antibodies, anti-thyroglobulin antibodies. Levothyroxine for Hashimoto's hypothyroidism may improve CSU control in thyroid-positive patients. The relationship is associative rather than causal — treating thyroid disease doesn't reliably resolve CSU, but it's important to identify.

Key statistics

~1%

global population point prevalence of chronic urticaria

WAO/EAACI

FDA/EMA 2014

omalizumab (Xolair) approved for chronic idiopathic urticaria refractory to antihistamines

FDA/EMA 2014

40-65%

complete symptom control with omalizumab 300mg/4 weeks

ASTERIA/GLACIAL trials

Up to 4×

the licensed antihistamine dose is recommended before stepping up to omalizumab

EAACI/WAO 2022

~40-50%

of CSU has autoimmune mechanism (anti-FCεRI or anti-IgE autoantibodies)

EAACI/Immunology

=3-vessel CAD

CSU quality of life impairment comparable to triple coronary artery disease (EuroQoL)

EuroQoL/EAACI

Chronic urticaria — treatment stepladder (EAACI/WAO 2022 guidelines)

Source: EAACI/WAO 2022. Antihistamine up-dosing before biologics; omalizumab highly effective for refractory CSU.

Glossary of key terms

Wheal and flare
Dermatology/UrticariaThe characteristic lesion of urticaria: wheal — a circumscribed, raised, erythematous, pruritic skin lesion with central pallor (blanching under pressure), appearing and disappearing within minutes to hours (individual lesions resolve within 24 hours by definition — if >24h, consider urticarial vasculitis). Flare — surrounding erythema (redness). Pathophysiology: mast cell degranulation → histamine release → H1 receptor activation → vasodilation + increased vascular permeability → wheal formation → sensory nerve activation → itch. Angioedema: similar process in the deeper dermis/subcutaneous tissues → non-pitting swelling of the face, lips, tongue, throat, hands, genitalia — potentially life-threatening when involving the airway.

UAS7 (Urticaria Activity Score 7)
EAACI/WAOThe standard validated outcome measure for CSU: patient self-records daily wheal number (0-3) + itch severity (0-3) for 7 days = UAS7 (range 0-42). UAS7 0-6: well-controlled; 7-15: mild; 16-27: moderate; 28-42: severe. Used in clinical trials (omalizumab) and clinical practice to assess disease severity and treatment response. The DLQI (Dermatology Life Quality Index) measures quality of life impact.

Omalizumab mechanism in CSU
Pharmacology/ImmunologyOmalizumab is a recombinant humanised anti-IgE monoclonal antibody — binding free IgE in circulation (not IgE already bound to cells). Mechanism in CSU: reduces free IgE → downregulates FCεRI (high-affinity IgE receptor) expression on mast cells and basophils (FCεRI expression depends on free IgE levels) → dramatically reduced mast cell responsiveness to IgE-mediated stimulation → rapid reduction in spontaneous mast cell activation → urticaria remission. Response: typically rapid (within 4-6 weeks of first injection); 300mg every 4 weeks is the approved dose. Not all patients respond (approximately 35% are non-responders).

Antihistamine up-dosing
EAACI/WAO 2022The EAACI/WAO international urticaria guidelines (2022 revision) recommend: if standard dose (1×) second-generation H1 antihistamine does not achieve symptom control within 2-4 weeks → increase dose up to 4× the licensed dose. Evidence: multiple controlled trials show improved symptom control at 2-4× dose with acceptable safety profiles for cetirizine, loratadine, bilastine, fexofenadine, desloratadine. Important: this is off-label prescribing in many countries (not in all) — inform patients. The evidence supports this approach before stepping up to omalizumab (which is far more expensive and requires specialist prescription).

Inducible urticaria types
EAACIA distinct group of urticarias triggered by specific physical stimuli — treated differently from CSU: Symptomatic dermographism (factitious urticaria): wheals induced by firm stroking of skin — the most common inducible urticaria. Cold urticaria: wheals with cold exposure; risk of systemic anaphylaxis with cold water immersion. Cholinergic urticaria: small 1-3mm wheals + flare with body temperature increase (exercise, hot shower, emotion). Solar urticaria: wheals with UV/visible light exposure. Pressure urticaria (delayed): erythema and deep swelling 4-6 hours after sustained pressure. Omalizumab is effective for cold urticaria and symptomatic dermographism.

Cyclosporin in CSU
NICE/EAACICyclosporin A (ciclosporin) is an immunosuppressant used as step 4 for omalizumab-refractory or intolerant CSU. Mechanism: inhibits T-cell activation and mast cell degranulation. Dose: 3-5mg/kg/day; monitor BP and renal function (nephrotoxic); maximum 3-6 months continuous use; taper slowly. Evidence: multiple controlled trials confirm efficacy; systematic review: approximately 65-70% response rate. Use as a bridging therapy before omalizumab access or in omalizumab non-responders.